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ABSTRACT 
Clinical Significance of Hepatopulmonary Syndrome  
in Biliary Atresia 
 
Eun Young Chang 
 
Department of Medicine  
The Graduate School, Yonsei University  
 
(Directed by Professor Seok Joo Han) 
 
 
(Objectives)The clinical characteristics of intrapulmonary shunt (IPS) that can lead to 
development of hepatopulmonary syndrome (HPS) in biliary atresia (BA) have not been 
well described. Therefore, we investigated the incidence and clinical significance of IPS 
and HPS in BA. (Methods)We evaluated 72 patients with BA between March 2010 and 
May 2013 for diagnosis of IPS by contrast-enhanced echocardiography (CEE) and HPS 
by arterial blood-gas analysis (ABGA). ABGA was performed only in patients who had 
IPS by CEE. Clinical data were reviewed retrospectively by grouping patients; normal 
group in which patients had no evidence of IPS by CEE, IPS group in which patients 
had IPS but did not have any evidence of HPS by ABGA, and HPS group in which 
patients had evidences of both of IPS and HPS. (Results)IPS was identified in 41 
patients (56.9%) and normal group was identified in 31 patients (43.1%). Six patients 
with IPS were excluded from data analysis because ABGA were not examined in these 
patients. IPS group included 20 patients, and HPS group included 15 patients. 
Compared to the normal group, the bilirubin level at the time of CEE and the hepatic 
2 
 
fibrosis score were significantly increased in the IPS group and HPS group, and liver 
transplantation was performed significantly more frequent in the HPS group. 
(Conclusion)The incidence of IPS in BA was considerably high. Patients with IPS have 
worse clinical outcomes than patients without IPS. The identification and 
close-monitoring of IPS in BA lead to favorable outcomes by preventing the late liver 
transplantation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
---------------------------------------------------------------------------------------- 
Key words: biliary atresia, intrapulmonary shunt, hepatopulmonary syndrome 
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I. INTRODUCTION 
 
An intrapulmonary shunt (IPS) is one of the long-term serious complications in 
chronic liver disease (1). The pathophysiology of IPS remains unclear. However, 
enhanced pulmonary production of nitric oxide and increased hepatic production of the 
vasodilator endothelin-1 in cirrhotic patients are associated with the development of IPS 
(2). If a patient with IPS and chronic liver disease is identified as having an arterial 
oxygen defect, hepatopulmonary syndrome (HPS) may be diagnosed (3). The presence 
of HPS is an important factor for predicting the survival of patients with chronic liver 
disease. In severe cases, patients should be evaluated for liver transplantation and 
closely monitored for liver failure (4). According to several retrospective studies about 
HPS in pediatric chronic liver disease patients, the prevalence of HPS is 8–20%, and 
early liver transplantation allows regression of pulmonary arteriovenous shunt (5-8).  
However, few clinical studies about IPS and HPS in biliary atresia (BA) have been 
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published. Moreover, the characteristics of patients with IPS in BA that can lead to 
development of HPS have not been well characterized. Therefore, we investigated the 
incidence of IPS and HPS in BA and evaluated their clinical significance. 
 
 
 
 
II. MATERIALS AND METHODS 
 
Between March 2010 and May 2013, children with BA who received a regular 
follow-up after the Kasai operation in the Department of Pediatric Surgery in Severance 
Children’s Hospital were prospectively recruited for evaluation of IPS. We considered 
that IPS would not be developed in young children before 6 months. Therefore, we tried 
to select the patients with ages from 12 months to six years. However, in some younger 
or older patients were also selected when they are needed the examination about IPS 
because their laboratory finding appeared the uncompensated status of liver. Patients 
with congenital heart disease with a right-to-left shunt and patients who underwent the 
liver transplantation were excluded in the study. And patients were excluded also when 
the patient’s guardians did not agree with CEE.       
Patients were evaluated for the presence of IPS and HPS using contrast-enhanced 
echocardiography (CEE) (9) and arterial blood–gas analysis (ABGA) including the 
alveolar-arterial oxygen gradient (AaDO2). IPS was identified as an arteriovenous shunt 
in CEE. HPS was diagnosed according to the criteria in the study by Rodriguez-Rosin et 
al (2) (Table 1). In all patients who were diagnosed with IPS or HPS, the chest x-rays 
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were performed. As a result, patients were identified without the intrinsic pulmonary 
abnormalities. Other additive chest examinations such as chest computed tomography or 
lung perfusion scan was not performed because we considered that these studies are 
invasive, expensive and unnecessary in young patients.  
 
 
TABLE 1. Diagnostic criteria for hepatopulmonary syndrome 
Variable Criterion 
Oxygen defect PaO2
* <80 mmHg or AaDO2
† ≥15 mmHg 
Intrapulmonary shunt Positive findings on CEE** within six heart-beats 
Liver disease All biliary atresia patients 
Degree of severity  
 Mild AaDO2 ≥15 mmHg, PaO2 ≥80 mmHg 
 Moderate AaDO2 ≥15 mmHg, PaO2 ≥60 mmHg to <80 
mmHg 
 Severe AaDO2 ≥15 mmHg, PaO2 ≥50 mmHg to <60 
mmHg 
 Very severe AaDO2 ≥15 mmHg, PaO2 <50 mmHg 
*Partial pressure of oxygen, †alveolar-arterial oxygen gradient, **contrast-enhanced 
echocardiography 
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1. CEE 
 
CEE was randomly performed by three pediatric cardiologists using an 
echocardiography device with 3- and 5-MHz probes with patients lying in a supine 
position. The four-chamber view was used to assess the right-to-left shunt. Ten 
milliliters of agitated saline was injected into the peripheral vein via a three-way 
stopcock. CEE was considered positive when micro-bubbles appeared in the left heart 
within six heart–beats after the right-atrial opacification (10, 11).  
 
2. ABGA 
 
For ABGA, the patient’s radial artery was punctured in a sitting position while 
breathing room air after resting for 5 minutes. Arterial hypoxemia was defined as partial 
pressure of arterial oxygen (PaO2) <80 mmHg (2). AaDO2 was calculated using the 
alveolar gas equation:  
AaDO2 = PAO2 – PaO2 = (FiO2 [Patm – PH2O] – [PaCO2/0.8]) – PaO2,  
where PAO2 denotes the partial pressure of alveolar oxygen, PaO2 is the partial pressure 
of arterial oxygen, FiO2 is the fraction of inspired oxygen, Patm is atmospheric pressure, 
PH2O is the partial pressure of water vapor at body temperature, and PaCO2 is the 
partial pressure of arterial carbon dioxide (0.8 corresponds to the standard gas-exchange 
respiratory ratio at rest); the normal range is 4–8 mmHg (2). If children were identified 
as not having IPS with CEE, ABGA was not performed due to the invasiveness of 
ABGA. 
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To evaluate the severity of liver cirrhosis, several clinical parameters were obtained 
by performing biochemical laboratory examinations, liver elastography (FibroScan® , 
Echosense, SA, Paris, France), gastroduodenoscopy, and abdomen ultrasonography 
during the same period as CEE.  
The clinical data were reviewed retrospectively and analyzed by grouping patients 
without IPS (normal group), patients with IPS without HPS (IPS group), and patients 
with IPS and HPS (HPS group).  
Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 
20.0. Continusous data were expressed as median value with range and categorical data 
were presented as number with percentage. The chi-square test or Fisher’s exact test 
were used to compare categorical variables and the Kruskal-Wallis test was used for 
comparisons of continuous variables between groups. A p value less than 0.05 was 
considered statistically significant. This study was approved by our institutional review 
board. 
. 
 
 
III. RESULTS 
 
Two hundred nineteen patients with BA have been receiving regular check-ups in our 
institution. According to scheduled follow-ups, 72 patients were examined with CEE for 
evaluation of IPS. Among these, 41 patients (56.9%) were identified as having IPS. 
Patients with IPS were examined with ABGA to diagnose HPS. Six patients with IPS 
were not examined with ABGA and were excluded from the grouping. Twenty patients 
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with IPS were identified as having IPS without HPS (IPS group). Fifteen patients with 
IPS were identified as having HPS (HPS group) (Fig. 1). The grades of HPS were 
identified as mild in 10 patients (13.9%), moderate in 4 patients (5.5%), and severe in 1 
patient (1.4%)(Table 2). 
 
 
FIG. 1. Patient classification 
(IPS: Intrapulmonary syndrome, CEE: contrast-enhanced echocardiography, HPS: 
hepatopulmonary syndrome, ABGA: arterial blood gas analysis) 
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TABLE 2. Incidence of hepatopulmonary syndrome 
Grade of hepatopulmonary 
syndrome 
N (%) 
Mild 10 (13.9) 
Moderated 4 (5.5) 
Severe 1 (1.4) 
Very severe 0 (0.0) 
Total 15 (100.0) 
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The clinical characteristics of patients according to the groups are summarized in 
Table 3. Ages at the Kasai operation and at the time of CEE were similar among the 
groups. Sex distribution was also not different among the groups. The jaundice-free rate 
within 6 months after the Kasai operation was lower in the IPS group compared to the 
normal group (75.0% vs. 87.1%, respectively) and was also lower in the HPS group 
compared to the IPS group (60.0% vs. 75.0%, respectively). However, the difference 
was not statistically significant (p=0.108). However, total bilirubin levels at the time of 
CEE were significantly higher in the HPS group compared to the normal group (total: 
1.9 mg/dL vs. 0.6 mg/dL, p = 0.005). And direct bilirubin levels at the time of CEE 
were significantly higher in the HPS group compared to the normal group (total: 1.2 
mg/dL vs. 0.2 mg/dL, p = 0.001). The liver stiffness score was also significantly higher 
in the IPS group compared to the normal group (15.5 kPa vs. 8.7 kPa, p<0.001) and also 
was higher in the HPS group compared to the IPS group (29.3 kPa vs. 15.5 kPa, 
p<0.001). 
The numbers of cholangitis events were not different among the groups. However, 
the numbers of patients who underwent liver transplantation were significantly higher in 
the HPS group compared to the normal group (33.3% vs. 0.0%, p=0.001). Except for 
one patient in the IPS group who died due to hematochezia, all patients in all groups 
survived with or without liver transplantation. 
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TABLE 3. Clinical details of patients according to the groups 
Characteristics 
Normal group 
(n=31) 
IPS group 
(n=20) 
HPS group 
(n=15) 
P-value 
Age at Kasai operation  
(days) 
56 (10–178) 66 (36–132) 60 (17–87) 0.072 
Age at the time of CEE  
(years) 
5.6 (0.3–13.1) 6.1 (0.4–15.4) 3.7 (0.5–12.4) 0.504 
Sex 
 (male/female, n) 
14/17 9/11 4/11 0.429 
Surgery (n)     
 Redo Kasai operation 0 2 2  
 LT** after Kasai operation 0 1 5  
Jaundice free within 6 months 
 after Kasai operation (n) 
27 (87.1%) 15 (75.0%) 9 (60.0%) 0.108 
Total bilirubin at the time of  
CEE (mg/dL) 
0.6 (0.2–5.9) 1.5 (0.4–4.0) 1.9 (0.6–21.2) 0.005‡ 
Direct bilirubin at the time of  
CEE (mg/dL) 
0.2 (0.1–5.1) 0.8 (0.1–3.5) 1.2 (0.3–17.1) 0.001‡ 
Liver stiffness score (kPa) 8.7 (3.1–75.0) 15.5 (6.1–41.3) 29.3 (12.0–75.0) <0.001§ 
Cholangitis events (n)    0.434 
 None 9 4 1  
 ≤ 3 times 12 11 5  
 >3 times 9 5 7  
 Unknown 1 0 2  
LT after diagnosis of HPS (n) 0 (0.0%) 1 (5.0%) 5 (33.3%) 0.001‡ 
*IPS: Intrapulmonary shunt, †HPS: Hepatopulmonary syndrome, ** LT: liver transplantation 
All continuous variables are reported as the median value with range. 
‡Comparison between the normal group and the HPS group was significant in post-hoc tests. 
§Comparisons between all three groups were significant in post-hoc tests.  
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IV. DISCUSSION 
 
In chronic liver disease including BA, IPS is sometimes identified as a long-term 
complication, and when accompanied by hypoxia, HPS may be diagnosed. HPS is 
defined as hypoxemia induced by intrapulmonary vascular dilatation associated with 
cirrhotic or non-cirrhotic liver disease and portal hypertension (3). Many reports have 
been published regarding the treatment and prognosis of HPS. However, few studies 
have been reported about IPS, including the incidence, pathophysiology, and clinical 
significance. Considering that HPS in uncompensated liver disease subsequently 
requires liver transplantation as a last treatment, the clinical significance of IPS should 
be more highly emphasized because IPS precedes the development of HPS (12).  
A few studies have reported the incidence of HPS in BA (1, 5, 6, 8, 13). In the 
literature, the incidences of HPS in children have been reported to be 8–28% in those 
with chronic liver disease and 17–19% in liver transplant recipients (5, 6, 8, 14-16). 
However, these incidences vary due to the heterogeneity of the disease and did not focus 
on the incidence of IPS in particular. Through our preliminary institutional study, we 
noticed that when considering BA only, the incidence of IPS was quite high. Therefore, 
we proceeded with this study and found that the incidence of IPS in BA was 56.9%, and 
the incidence of HPS was 20.8%. These high incidences of IPS and HPS have not been 
previously reported. Thus, we believe that this is the first and largest study about IPS 
and HPS that is restricted to BA.  
However, the clinical meaning of this high incidence of IPS is not well understood. 
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According to our results, indicators of a poor clinical condition such as high bilirubin 
levels and high liver stiffness scores were significantly higher in the IPS group than in 
the normal group, and were also higher in the HPS group compared to the IPS group. 
Liver transplantation rate was also higher in the HPS group compared to the IPS group 
and in the IPS group compared to the normal group. These results indicate that patients 
with IPS are more likely to worsen clinically or to develop HPS than patients without 
IPS in BA. In other words, the presence of IPS in BA may lead to potential morbidities.  
One significant finding leading to diagnosis of HPS is an arterial oxygenation defect. 
However, few patients with HPS complain of hypoxic symptoms, and monitoring of 
hypoxia is considerably difficult in pediatric patients during the follow-up period. 
Therefore, to detect the presence of IPS, even absence of clinical symptoms, 
examination for IPS and close monitoring for the development of HPS are crucial.  
Once a diagnosis of HPS is made, the process of undergoing liver transplantation 
should proceed. In the past, severe hypoxemia due to HPS was considered a 
contraindication for liver transplantation. However, current medical therapies for HPS 
are not effective, and liver transplantation is the only successful treatment (12). At 
present, the prognosis of BA after liver transplantation is favorable, with 5-year-survival 
rate 85–98% (17). Although HPS is a rare cause of liver transplantation in BA, it is the 
only treatment that can reverse HPS. Therefore, early diagnosis of IPS and early liver 
transplantation to treat HPS are important.  
The pathophysiology of IPS in BA is unclear. However, according to several studies, 
nitric oxide may be the cause of IPS. In dilated capillaries, less gas exchange occurs 
with oxygen-rich alveoli, resulting in a ventilation-perfusion mismatch (11). In animal 
models of IPS, elevated nitric oxide levels are detected in the lung of rats, and are 
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believed to be the most probable cause of IPS (18-20). In a recent study, angiogenesis, 
which is mediated by vascular endothelial growth factor A produced by activated 
intravascular monocytes, was shown to be a key contributor to the pathogenesis of IPS 
(21). However, this discovery is confined to animal models. Therefore, to define the 
clinical significance of IPS more accurately, further studies on the pathophysiology of 
IPS and HPS are needed in chronic liver diseases including BA. 
This study has some limitations. First, when children cry during ABGA, the 
reliability of the procedure is unclear in terms of how the reading reflects the exact 
degree of hypoxemia. Second, this study did not include all our patients with BA 
because the follow-up schedule was different among patients. Lastly, all patients who 
underwent liver transplantation underwent surgery after diagnosis of HPS. However, the 
definitive cause of liver transplantation in patients with IPS and HPS is ambiguous. The 
indications of liver transplantation in our institution are: impending liver failure with 
signs of hepatic synthetic dysfunction such as growth failure, hypoalbuminemia, and 
coagulopathy, intractable portal hypertension such as uncontrolled variceal bleeding and 
intractable ascites, and hepatopulmonary syndrome (HPS). However, we did not have 
any patients who received liver transplantation just to resolve HPS. All patients with 
HPS in this study did not have any symptoms of HPS like dyspnea when they had been 
diagnosed HPS because they were carefully followed for the detection of IPS. Therefore, 
all patients with HPS who received liver transplantation in our study had another 
surgical indication of liver transplantation, but the fact of evidence of HPS influenced 
the decision of liver transplantation.  
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V. CONCLUSION 
 
Our study is the one of the largest studies to investigate IPS and HPS confined in BA 
only. The incidences of IPS and HPS were considerably high in BA. Patients with IPS 
have worse clinical outcomes than patients without IPS. Therefore, the presence of IPS 
should be considered a “hidden morbidity”. Check-ups to look up for the presence of 
IPS and close monitoring of patients with IPS should be done so that early diagnosis of 
HPS and appropriate treatment, such as timely liver transplantation, can be performed, 
leading to a favorable outcome.  
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ABSTRACT (IN KOREAN) 
담도 폐쇄증에서 간폐증후군의 임상적 의의 
 
<지도교수 한석주> 
 
연세대학교 대학원 의학과 
 
장   은   영 
 
(배경) 만성 간질환 환자에서 폐내단락이 있는 경우에 
저산소증까지 발생할 경우 간폐증후군으로 진행할 수 있는데 
담도폐쇄증에서는 아직까지 잘 알려지지 않고 있다. 이에 
담도폐쇄증에서의 폐내단락과 간폐증후군의 유병율과 임상적 
의의에 대해 알아보고자 하였다. (방법) 2010년 3월부터 2013년 
3월까지 72명의 담도폐쇄증 환자에서 조영증강 심초음파를 
이용하여 폐내단락을 검사하였고, 이 중 폐내단락이 진단된 
경우에는 추가로 동맥혈가스분석을 통하여 간폐증후군 유무를 
확인하였다. 결과에 따라 정상군, 폐내단락만 있는 군, 
간폐증후군까지 있는 군으로 분류하여 결과를 분석하였다. (결과) 
전체환자 중 정상군은 31명 (43.1%) 이었고, 41명 (56.9%) 에서 
폐내단락이 진단되었다. 이 중에서 동맥혈가스검사를 시행하지 
않은 6명을 제외하고 폐내단락만 있는 경우는 20명이였으며, 
간폐증후군까지 있는 경우는 15명이었다. 정상군에 비해 
폐내단락군과 간폐증후군군에서 혈청 빌리루빈 수치와 
간섬유화점수가 유의하게 증가되어 있었고, 간폐증후군 
환자에서 간이식이 더 유의하게 시행되었다. (결론) 
담도폐쇄증에서 폐내단락의 유병율은 상당히 높았으며, 
폐내단락이 있는 환자는 그렇지 않은 환자에 비해 임상적으로 
더 나쁜 예후를 보였다. 따라서 담도폐쇄증 환자에서 
폐내단락의 발생을 유심히 살핀다면 적절한 시기에 간이식을 
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시행하게 함으로써 좀 더 나은 예후를 보일 수 있을 것으로 
판단된다.  
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